Scinai Immunotherapeutics Ltd. Sponsored ADR (SCNI)
(Delayed Data from NSDQ)
$1.60 USD
+0.09 (5.96%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $1.60 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SCNI 1.60 +0.09(5.96%)
Will SCNI be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SCNI based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for SCNI
Scinai Immunotherapeutics' PC111 featured in peer-reviewed publication
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Scinai (SCNI) Highlights Progress with PC111 in Dermatological Treatments
Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy ...
Why Celestica Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket